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Available online 17 July 2016To replace the Draize skin irritation assay (OECD guideline 404) several test methods based on reconstructed
human epidermis (RHE) have been developed and were adopted in the OECD test guideline 439. However, all
validated testmethods in the guideline are linked to RHE provided by only three companies. Thus, the availability
of these test models is dependent on the commercial interest of the producer. To overcome this limitation and
thus to increase the accessibility of in vitro skin irritation testing, an open source reconstructed epidermis (OS-
REp) was introduced. To demonstrate the capacity of the OS-REp in regulatory risk assessment, a catch-up vali-
dation study was performed. The participating laboratories used in-house generated OS-REp to assess the set of
20 reference substances according to the performance standards amending the OECD test guideline 439. Testing
was performed under blinded conditions. The within-laboratory reproducibility of 87% and the inter-laboratory
reproducibility of 85% prove a high reliability of irritancy testing using the OS-REp protocol. In addition, the pre-
diction capacity was with an accuracy of 80% comparable to previous published RHE based test protocols. Taken
together the results indicate that the OS-REp test method can be used as a standalone alternative skin irritation
test replacing the OECD test guideline 404.
© 2016 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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The epidermis forms the outermost barrier between the human
body and the environment and is thus exposed to various potentially
harmful substances. To test the potential of substances to cause skin ir-
ritation, the Draize assay was developed and implemented as test
guideline 404 of the Organization for Economic Co-operation and De-
velopment (OECD) (Draize et al., 1944). However, due to the limited rel-
evance of results from this animal assay for humans and animal welfare
concerns, in vitro models have been developed to assess the skin irrita-
tion potential of chemicals (Fentem et al., 1998; Stobbe et al., 2003).The
legislation worldwide endorses the introduction of alternative test
methods that complywith the concept of reduction, refinement and re-
placement of animal experimentation introduced by Russell and Burch
(Russell et al., 1959). In the European Union, clear priority is given for
animal free tests due to the provisions of the legislation for the Registra-
tion, Evaluation, Authorization and Restriction of Chemicals (REACH;
EU, 2006) and the European Union Cosmetics Regulation (EU, 2009).
The latter regulation put a stepwise ban of animal tests for cosmetic
products and ingredients into force. The final step was enforced inthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Fig. 1. Procedure for the conduction of a validation study for skin irritation testing (SIT). In
the classical approach (A) the employed reconstructed human epidermis (RHE) is
provided by the test developer to the additional two laboratories, where the models are
used in the SIT validation test runs. In the present study (B) all participating laboratories
established their own OS-REp production and then used the in-house produced models
in the SIT.
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gredients tested on animals after this deadline.
The prediction of skin irritation using an alternative approach is fea-
sible by employing in vitro testmethods based on reconstructed human
epidermis (RHE), which is based on human epidermal keratinocytes
(hEK). The models emulate the morphology, structure and metabolism
of the human epidermis accurately (Rosdy and Clauss, 1990). Currently
several RHE models are commercially available from various producers
and academic institutes (DeWever et al., 2013; Groeber et al., 2011) and
have been used for different research questions such as, skin corrosion
(Kandárová et al., 2006), skin irritation (Cotovio et al., 2005), skin barri-
er formation (Thakoersing et al., 2013) and skin absorption (Schäfer-
Korting et al., 2008). Currently the epiCS™ model by CellSystems
(Pratt et al., 2014), the SkinEthic RHE (Alépée et al., 2014) and EpiSkin
™ (Alépée et al., 2016) model by L'Oréal, the EpiDerm™ model by
Mattek (Chapman et al., 2014) and the ATERA-RHE by ATERA can be
purchased worldwide. Additionally, the LabCyte EPI model by J-Tech
(Katoh et al., 2009) and the KeraSkin-VM™ by MCTT Inc. (Jung et al.,
2014) are available in Japan and Korea. Of the commercial RHE, two
models, namely the EpiDerm™ and the EpiSkin™, were part of the
first skin irritation validation study sponsored by the European Union
Reference Laboratory for Alternatives to Animal testing (EURL-
ECVAM). After optimization, themethodswere found to be scientifically
valid as a standalone method to identify skin irritants and were imple-
mented by theOECD in the test guideline 439 (OECD, 2015a).Moreover,
the results are the basis for the performance standards for in vitro skin
irritation test methods based on reconstructed human epidermis
(OECD, 2015b; Spielmann et al., 2007). Following the initial validation
study, the SkinEthic™ RHE (Alépée et al., 2010) and the LabCyte EPI-
MODEL™ (Kojima et al., 2013) were validated in catch-up validation
studies and integrated in the test guideline 439.
However, the validated test protocols are linked to a limited number
of models produced and marketed by a few companies only. Hence, all
validated tests are dependent on the availability and the commercial
strategies of the suppliers. An unrestricted approach has become possi-
ble by an open source reconstructed epidermis (OS-REp) established by
the Henkel AG &Co. KGaA (De Wever et al., 2013, 2015).
Comparable to the open source concept in information technology, in
which the source code of software is openly accessible, the OS-REpmodel
will include the publication of the production protocol without legal re-
strictions (Bagozzi and Dholakia, 2006; Hertel et al., 2003; Lakhani and
VonHippel, 2003). Thus, any laboratory can use OS-REp for irritation test-
ing and other research purposes without being dependent on commer-
cially available models. Thereby the open source concept could foster
the dissemination and implementation of skinmodels especially in coun-
tries with customs regulations that restrict the import of tissuemodels or
budget restricted research laboratories. Moreover, open source allows
end users to amend the source code, to improve the program or adapt it
to a specific purpose. In the framework of alternative test methods it is
envisioned that this philosophy will encourage a constant refinement of
themodel. However, it should benoted that once amodel is implemented
in a test procedure the model cannot be changed without again demon-
strating the validity of the test methods.
The OS-REp is based on an initial protocol (Lemper et al., 2013;
Poumay et al., 2004), refined by Henkel (HEN) and employed in an ini-
tial skin irritation test. In order to become accepted by regulatory au-
thorities, we performed and describe a catch-up validation study with
the OS-REp according to the EURL-ECVAM performance standards for
in vitro skin irritation testing, previously an integral part of the OECD
TG 439 (OECD, 2015b). In Phase I of the two-tiered approach a blinded
studywas conducted, in which all OS-REpmodels were exclusively pro-
duced at HEN and shipped to all participating laboratories. This study
resulted in an overall accuracy of 75%. In addition, the skin irritation
testing process was refined regarding the handling of volatile irritating
test substanceswhile leaving the procedural details of the testing proto-
col unchanged.Here we present the results of the Phase II of the catch-up validation
study to achieve regulatory acceptance for skin irritation testing. Due to
structural, mechanistic and procedural similarity of the OS-REp model
and the OS-REp skin irritation testing protocol with accepted test
methods, the performance standards for in vitro skin Irritation testing
are applicable to reduce the acceptance process (OECD, 2015b). In the
present study HEN distributed only the standard operating procedures
(SOP) for hEK isolation, OS-REp production and skin irritation testing
to two additional independent laboratories. After a transfer phase all
laboratories established their own hEK batches from diverse donors,
generated their own OS-REp models and then only used the in-house
produced models for the validation runs.
2. Material and methods
2.1. Study design
The catch up validation study was conducted according to the per-
formance standards (OECD, 2015b) at the lead laboratory HEN, the
Fraunhofer Institute for Interfacial Engineering and Biotechnology as
part of the Fraunhofer Gesellschaft (FHG) and the Institute of Pharmacy
at the Freie Universität Berlin (FUB). Each laboratory established own
hEK batches and produced its own OS-REp in the respective facilities
(Fig. 1). Subsequently, the models were employed to test the same set
of 20 reference substances in each laboratory in three to five indepen-
dent runs at different occasions. Test substanceswere coded and distrib-
uted by the Biotesys GmbH (Esslingen, Germany), safeguarding that the
testing in the laboratories was conducted under blind conditions. The
reference substances comprised ten irritants, i.e. category 2 substances
according to the United Nations Globally Harmonized System of Classi-
fication and Labelling of Chemicals (UN GHS), and ten non-irritants, i.e.
no category substances (Table 1) (United Nations, 2015).
In addition to the blinded test substances, two controls were includ-
ed in each test run. As a negative control that controls for insufficient tis-
sue viability, phosphate buffered saline (PBS, Life Technologies) was
applied to the models. A 5% aqueous solution of sodium dodecyl sulfate
(SDS, Sigma-Aldrich; Steinheim, Germany) was used as the positive
control.
Per test run, each substance and each control was tested on three tis-
sue replicates. Only test data, whichmet all acceptance criteria specified
in the SOPs were considered valid for data analysis. In case the standard
deviation between run replicates exceeded 18%, the respective sub-
stance was re-tested up to two times. However, if the acceptance
criteria for the negative control and the positive control were not met,
Table 1
List of the 20 reference chemicals defined in theOECDperformance standards (OECD, 2015a, 2015b), whichwere used to assess the reliability and predictive capacity of the OS-REp based
skin irritation test. The chemicals comprise 10 non-irritants (no category) and 10 irritants (category 2) according to the UN GHS classification.
No. Test substances CAS Number Supplier Physical state In vivo UN GHS category
1 1-bromo-4-chlorobutane 6940-78-9 Sigma-Aldrich liquid, clear No cat.
2 4-methyl-thio-benzaldehyde 3446-89-7 Sigma-Aldrich liquid, clear, yellow No cat.
3 allyl phenoxy-acetate 7493-74-5 Sigma-Aldrich liquid, clear, colorless No cat.
4 cinnamaldehyde 104-55-2 Sigma-Aldrich liquid, clear, yellow No cat.
5 diethyl phthalate 84-66-2 Sigma-Aldrich liquid, clear No cat.
6 heptyl butyrate 5870-93-9 Sigma-Aldrich liquid, clear, colorless No cat.
7 hexyl salicylate 6259-76-3 Sigma-Aldrich liquid, clear, colorless No cat.
8 isopropanol 67-63-0 AppliChem liquid, clear, colorless No cat.
9 methyl stearate 112-61-8 Sigma-Aldrich solid, white No cat.
10 naphthalene acetic acid 86-87-3 Sigma-Aldrich solid, white No cat.
11 1-bromohexane 111-25-1 Sigma-Aldrich liquid, clear, colorless Cat. 2
12 1-decanol 112-30-1 Sigma-Aldrich liquid, clear, colorless Cat. 2
13 1-methyl-3-phenyl-1-piperazine 5271-27-2 Sigma-Aldrich solid, yellowish Cat. 2
14 2-chloromethyl-3,5-dimethyl-4-methoxypyridine HCL 86604-75-3 Sigma-Aldrich solid, white Cat. 2
15 benzenethiol,5-(1,1-dimethylethyl)-2-methyl 7340-90-1 Acros-Organics liquid, clear, colorless Cat. 2
16 cyclamen aldehyde 103-95-7 Sigma-Aldrich liquid, clear, colorless Cat. 2
17 di-n-propyl disulphide 629-19-6 Sigma-Aldrich liquid, clear, colorless Cat. 2
18 heptanal 111-71-7 Sigma-Aldrich liquid, clear, colorless Cat. 2
19 potassium hydroxide (5% aq) 1310-58-3 Carl Roth liquid, clear, colorless Cat. 2
20 tetrachloroethylene 127-18-4 Sigma-Aldrich liquid, clear, colorless Cat. 2
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full. Thus, a maximum of five repeats for a single test substance, or five
repeats for a complete test run were allowed. For quality control, the
participating laboratories submitted the results to Seh consulting ser-
vices (Paderborn, Germany) for independent statistical analysis. Addi-
tionally, auditable information was provided in a method
documentation sheet as required by quality assurance systems such as
GLP or ISO 17025.
2.2. Open source reconstructed epidermis
The OS-REp is based on a protocol published by Poumay et al.
(Poumay et al., 2004) which was further refined in order to improve
lifetime and architecture of the tissues. In the protocol, hEK were isolat-
ed from foreskin sample after receiving an informed consent and ethical
approval. Subsequently, hEKs were seeded on the polycarbonate mem-
branes of respective cell culture inserts (Millicell-PVF, pore size 0.4 μm,
Merck Millipore; Darmstadt, Germany), in the third passage with a cell
density of 5 × 105 hEK/cm², in 500 μL EpiLife® SubmerseMediumbased
on EpiLife® supplemented with 0.2% v/v Bovine pituitary extract, 1 μg/
mLml Recombinant human insulin-like growth factor-I, 0.18 μg/mL Hy-
drocortisone, 5 μg/mL Bovine transferrin, 0.2 ng/mL Human epidermal
growth factor (all from Life Technologies; Darmstadt, Germany) and
1.5 mM CaCl2 (Sigma-Aldrich Chemie; Munich, Germany). To ensure
sufficient supply to the hEK 20 OS-REp were cultured in 38mLmedium
in a 145 mm petri-dish (Greiner Bio One, Frickenhausen, Germany).
Medium was changed after 24 h to EpiLife® air–liquid–interface (ALI)
medium, additionally containing 73 μg/mL L-ascorbic acid 2-phosphate
and 10 ng/mL keratinocyte growth factor (both Sigma-Aldrich). During
the air–liquid–interface culture 10OS-REpwere cultured per petri-dish.
Within a 19 days culture phase, in which the medium was replaced by
fresh air–liquid–interface medium three times a week, a well-stratified
epidermal layer was formed and the models could be used for skin irri-
tation testing. Cell and tissue models were cultured at 37 °C and 5% CO2
in a humidified incubator.
2.3. Quality control
2.3.1. Histology
Tissue samples were fixated in Bouin's fixation agent (Sigma-Al-
drich; Steinheim, Germany) for 1 h, washed in tab water for 2 h and
then embedded in paraffin. Subsequently, histological cross-sectionsof 3 μmwere generated. For an overview of the general histological fea-
tures tissue slides were stained with hematoxylin and eosin.
2.3.2. Assessment of barrier function
To determine the skin barrier, triplicates of OS-REp were challenged
with 25 μL of a 1% solution of Triton-X 100 in PBS for 0, 1.5, 3, 4.5 and 6 h.
After washing the models 8 times with 600 μL PBS tissue viability was
assessed using the 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazoliumbromid (MTT) assay (OECD, 2015a). For that OS-
REp were placed in 200 μL MTT solution (1 mg/mL) (Sigma-Aldrich)
for 3 h in a humidified atmosphere with 37 °C and 5% CO2. The MTT re-
duction was then quantified by extracting the precipitated blue
formazan salt with 2 mL 2-propanol and measuring the optical density
of the extract at a wavelength of between 540 and 600 nmusing a spec-
trophotometer. After correcting the data using 2-propanol as blank the
relative tissue viability was calculated for each OS-REp by normalizing
the corrected optical density values to the models that have not been
treated with Triton-X 100 (0 h; Spielmann et al., 2007). From these
data the ET50-value, meaning the incubation time in Triton-X 100 solu-
tion that reduced tissue viability to 50%,was calculated. Based on histor-
ical data and the outcome of Phase I of the validation study the ET50
must be equal to or bigger than 2 h.
2.4. Skin irritation test
2.4.1. Test protocol
The skin irritation test was conducted according to the protocol as
described in Phase I of the validation study. Briefly, 25 μl of liquid test
substances or 25 μg of solid substances (moistened with 25 μ μl PBS)
were applied to the surface of the models. After a treatment time of 35
minutes (Mewes et al., 2016) at room temperature the OS-REp were
carefully rinsed 8 times with 600 μL PBS each. Additionally, the tissues
were immersed 5 times in 500 mL fresh PBS. Following a 42 h post-ex-
posure incubation at 37 °C and 5% CO2 tissue viability was assessed
using the MTT assay. Tissue viability of treated models was normalized
to the negative control, which was set to 100%.
2.4.2. Prediction model
In the current study, the prediction model defined in the perfor-
mance standards was applied (OECD, 2015a, 2015b). Thus, to predict
skin irritation from the viability data a 50% threshold was used. In
case, the mean viability after the skin irritation testing was above 50%,
a substance was considered as non-irritating or ‘no category’ according
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below 50% were classified as irritating or ‘Category 2’ according to the
UN GHS system.
2.4.3. Acceptance criteria
In concordancewith the performance standards for in vitro skin irri-
tation testing, each OS-REp batch used in the skin irritation test had to
meet predefined acceptance criteria based on historical data of the
method developers and on the results of Phase I of the validation
study (Mewes et al., 2016). All PBS exposed OS-REp (negative control)
had to show a high viability, with an absolute optical density between
0.6 [relative units] and 1.8 [relative units], and the relative viability fol-
lowing the exposure to 5% aqueous solution of SDS (positive control)
had to be below 10%. The variability of the relative viabilities of the tis-
sue replicates is used as an acceptance criterion for the test procedure,
since problems such as defects in single tissues, effects of specific sub-
stanceswith inherently variable responses, or inappropriate application
or dosing may result in excessive replicate variability. The standard de-
viation of the viability is used tomeasure this variability. A standard de-
viation of 18% or higher was considered as not acceptable and thus
required a re-testing.
3. Results
3.1. Transfer phase
A vital aspect of this validation study was that all test laboratories
produced their own OS-REp models with comparable properties and
quality. Thus, the SOPs for the hEK isolation, cell culture, OS-REp assem-
bly and skin irritation testing were transferred by the test developer
HEN to the two participating laboratories FUB and FHG. The transfer
process was organized in two phases. First, the technical staff from the
partner laboratories was trained by HEN employees at HEN laboratories
according to the SOPs. Next, the participating laboratories received hEK
batches from the tests developer for the production of OS-REp and the
morphology was then compared to OS-REp grown by HEN in parallel.
The histological architectures of these tissue models were nearly indis-
tinguishably from each other. In the second phase, the participating lab-
oratories established own hEK batches and subsequently generated OS-
REp from these cells. The quality of the OS-REp was assessed by histol-
ogy, tissue viability (absolute optical density, MTT assay) and the ET50-
values indicative for the barrier function. Themean value of the absolute
optical density produced at FUBwas 0.68 [relative units] +/- 0.15 [rela-
tive units] and at FHG 1.28 [relative units] +/- 0.13 [relative units]. The
barrier function at FUB and FHG, too, was well above the acceptance
limit of 2 h of the OS-REp skin irritation SOP (data not shown).
3.2. Acceptance criteria
Generally the histological architecture of the OS-REp is highly compa-
rable to the human epidermis (Fig. 2). This includes a clear single-layered
Stratum basale, consisting of hEK arranged in a palisade-like pattern, at
least 2-3 cell layers in the stratum spinosum, at least 2-3 layers of Stratum
granulosum cells, characterized by its flattened cell polarity, absence ofFig. 2. Histological morphology of OS-REp. Hematoxylin and eosin stained cross section of OS
generated by seeding primary human epidermal keratinocytes (hEK) on a polycarbonate me
(stratum basale) with cubic shaped hEK, the spinous layer (stratum spinosum) containing ce
granula were additionally visible. After these viable cell layers, a corneous layer of non-viable hnuclei and presence of darkly-stained granules and a Stratum corneum,
consisting of several layers of cornified hEK. Additionally, no histological
differences are detectable between OS-REp models that were generated
in the 3 laboratories (HEN, FUB and FHG).
In each experiment, a negative control was included in order to
demonstrate appropriate viability of the tissue model. Three tissues
were treated with PBS and their viability assessed using the MTT
assay. The mean optical density in all test runs in the three laboratories
fell within the acceptable optical density interval ranging from 0.6 [rel-
ative units] to 1.8 [relative units] as defined in the OS-REp quality
criteria (Fig. 3, A). Additionally, each experiment included a positive
control (5% SDS solution) in order to demonstrate the sensitivity of
the tissue model to a known irritant. Fig. 3 B depicts the relative mean
cell viabilities of the three tissue replicates and the respective standard
deviation for each experiment of all laboratories. The mean viability of
the positive control tissue replicates ranging from 0.3 to 3.1% was al-
ways clearly below the maximum acceptable value of 10% as defined
for OS-REp. The mean value of the ET-50 of all test runs and re-tests
was above the acceptable lower limit of 2 h (Fig. 3, C).
In 188 tests, the standard deviation values exceeded the acceptance
cut-off value of 18% only 8 times (Fig. 3, C) and thus required a re-testing.
To compensate for not acceptable variability in the first three experi-
ments, the laboratories re-tested substances up to twice. All re-tests had
acceptable standard deviation, so that for all 20 substances a complete
data set in all three laboratories was available (Supplementary Table 1).
3.3. Reliability
Concordance of classifications between independent runs in labora-
tories was used to assess the within-laboratory reproducibility. Classifi-
cations were derived from relative cell viabilities, which are presented
in Fig. 4, by applying the prediction model (non-irritant, if N50% viabil-
ity; irritant, if ≤50% viability). Furthermore, Supplementary Table 2
gives an overview over the results of the three valid test runs and the
two re-rest at the laboratories of HEN, FUB and FHG. A substance was
considered reproducible within a laboratory if the three runs resulted
in a concordant classification. At HEN, 16 of the 20 test substances
gave concordant results resulting in a within-laboratory reproducibility
of 80%. FHG had a within-laboratory reproducibility of 95%, with di-n-
propyl disulphide being the only substance with discordant classifica-
tions. At FUB three substances had discordant classifications resulting
in a within-laboratory concordance of 85%. The between-laboratory re-
producibility was assessed by the concordance of classifications be-
tween the laboratories. Therefore, the final classification for each test
substance per laboratory was obtained by using the mean viability
over the three valid runs. 17 of the 20 substances gave concordant clas-
sifications which resulted in a between laboratory reproducibility of
85%. Table 2 contains a summary of the obtained results of the OS-REp
skin irritation validation study in comparison to the acceptance limits.
3.4. Predictive capacity
The predictive capacity in this catch-up validation study was deter-
mined by comparing the in vitro classification obtained in the OS-REp-Rep generated in the 3 participated laboratories (HEN, FUB and FHG). The models were
mbrane. hEK differentiated into all layers, observed in native epidermis. The basal layer
lls with a more flatten morphology and the granular layer (stratum granulosum) where
EK was formed (stratum corneum). Scale bar equals 50 μm.
Fig. 3. Acceptance criteria of the OS-REp during the validation runs. The study comprises three full test runs (1st R, 2nd R and 3rd R) and two re-tests (1st RT and 2nd RT) for substances
where the standarddeviation of themean results exceeded the 18% limit andwas conducted at HEN, the FUB and FHG. All OS-REpbatchesmet the required absolute optical density (OD) of
the negative control (NC) (A),the viability of the positive control (PC) (B), and the ET50 value (C). Dotted lines indicate the defined limits of the respective acceptance criterion. It is to be
noted that at the HEN and FUB laboratories only one re-test was necessary to achieve a comprehensive data set. Image D depicts the distribution of the standard deviation (SD) in the test
runs for all test substances (TS 1–TS 20).
258 F. Groeber et al. / Toxicology in Vitro 36 (2016) 254–261skin irritation test with the reference in vivo UN GHS classifications
based on the Draize skin irritation test (OECD, 2015b). Three of the
non-classified substances, namely 1-bromo-4-chlorobutane, 4-methyl-
thio-benzaldehyde and cinnamaldehyde were classified as irritating
by all three laboratories (Fig. 4, A) resulting in a specificity of 70%. The
sensitivitywas at least 80% in all laboratories.WhileHEN correctly iden-
tified all category 2 substances (100% sensitivity), FHGmisclassified two
category 2 substances (80% sensitivity) and FUB one category 2 sub-
stance (90% sensitivity) as non-irritating (Fig. 4, B). Consequently,
HEN reached an accuracy of 85%, FHG of 80% and FUB of 75% (Table 2).
4. Discussion
Four epidermal models produced by three companies have been in-
cluded in OECD TG 439 based on validation exercises (OECD, 2015a).
The validation of a model includes the publication of the protocols for
the skin irritation test, yet the exact manufacturing process for the re-
spective tissue models is generally not disclosed by the manufacturer
and hence not openly accessible, which might limit the scientific prog-
ress and dissemination of animal-free test methods. As an alternative
approach, the open source concept was introduced by HEN into the
field of alternative test methods that also includes the publication of
manufacturing SOPs (De Wever et al., 2013, 2015). The availability of
the models will be increased and the respective test can be conducted
independently from commercial suppliers. This is of special interest in
countrieswith customs hurdles for the import of commercially available
living tissues e.g. Brazil, produced in the United States, Japan or the EU.
Moreover, a broad scientific community can contribute to the further
refinement of the model without legal restrictions.
Even though the open source concept allows and even encourages
the constant refinement of the models, a vital aspect of regulatory ac-
cepted testing is that the results must be reproducible irrespective of
the tissue model producer and applicant, respectively. Therefore, if the
OS-REp skin irritationmethod is used for regulatory purposes, introduc-
tion of changes to the OS-REp manufacturing or skin irritation testingprotocols may render the method unsuitable for these purposes as a
changed protocol might have unintended side effects on the respective
testmethod. In this regard, the open source concept in the framework of
alternative methods differs substantially from open source in informa-
tion technology as changes need to be approved and the validity of
the test methods has to be demonstrated again.
Since for the irritation testing in the OS-REp model not only the test
protocols are transferred but also the whole manufacturing process has
been performed by the end user, this study evaluated if a naïve labora-
tory can perform the entire process at a high standard, whichmeans the
production of OS-REpmodels of sufficient quality in addition to the con-
duct of skin irritation testing. Although thewithin-laboratory-reproduc-
ibility in two laboratories was below the acceptance limit of 90%, the
between-laboratory-reproducibility was with 85% above the limit of
80% specified in the OECD performance standards (OECD, 2015a,
2015b). The outcome of the transfer phase thus proved that the SOPs
for OS-REp model production and skin irritation testing have been suc-
cessfully transferred to the laboratories at the FUB and the FHG. Howev-
er, to ensure the transferability of the protocols and thus reliable test
results, a qualified training for a naïve laboratory that wishes to use
the OS-REpmodel is proposed in order to implement all SOPs diligently.
Following this initial qualification a fully blinded catch-up validation
study according to the performance standards (OECD, 2015b) was con-
ducted, in which each laboratory solely employed OS-REp generated in
the respective facility. Although themodels were produced at indepen-
dent facilities, all test runs met the predefined quality criteria showing
the good transferability of the method.
Of note, in this study hEK from 4 different donorswere employed. At
HEN and FUB one cell donor and at FHG two donors were employed to
generate models whereas cell batches were not pooled. Thereby the re-
sults reflect individual variability towards skin irritants within the pop-
ulation to a greater extent than previous work, which becomes evident
in the discordant classification of few category 2 test substances. In the
valid test runs 1-bromohexane (substance 11) and di-n-propyl di-
sulphide (substance 17) were misclassified at FHG and 1-methyl-3-
Fig. 4. Results of the blinded skin irritation testing. The effect of 10 non-irritants (A) and 10 irritants (B) on OS-REp produced at the respective test facility was investigated using the MTT
assay, viability of thenegative control (PBS)was set to 100%. Thefigures show the results of the three valid test runs at the laboratories of HEN, FUB and FHG. In each test run 3OS-REpwere
used per test substance and the result of each test run is depicted as mean viability (back squares) and standard deviation (error bars). In case the standard deviation exceeded 18%, re-
testing (up to twice)was conducted for the respective substance. A substancewas classified as a non-irritant if themean viabilitywas higher than 50%. In case themean viabilitywas equal
to or below 50% the substance was categorized as an irritant.
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Employing the EpiDerm™ model, 1-methyl-3-phenyl-1-piperazine
was also misclassified in the initial validation study in one out of threeTable 2
Summary of the OS-REp skin irritation validation study. The table shows the results for the
three test laboratories HEN, FUB and FHG in comparison to the acceptance limits defined
in theOECDperformance standards (OECD, 2015a, 2015b). Furthermore, the overallmean
values for all participating laboratories are presented (Mean).
Parameter Acceptance
limit
HEN FUB FHG Mean
Sensitivity [%] 80 100 80 90 90
Specificity [%] 70 70 70 70 70
Accuracy [%] 75 85 75 80 80
Within-laboratory-reproducibility
[%]
90 80 85 95 87
Inter-laboratory-reproducibility [%] 80 85test runs (Spielmann et al., 2007). Even though this problem could be
omitted in the subsequent optimization phase, it shows a tendency of
the test substance to yield in discordant results. However, as the sensi-
tivity was 90%, all laboratories met the OECD acceptance criterion of
≥80%.
Misclassification of 1-bromohexane was seen in the OS-REp model
as well as in the KeraSkin™ and Labcyte model (Jung et al., 2014;
Kojima et al., 2013). Furthermore, human in-vivo-data suggest that
the irritating effect of 1-bromohexane is dependent on the individual
genetic background of a human as only 16 out of 30 test persons reacted
positively in a 4 hour patch test (Jírová et al., 2010). At FHG two test
runs conducted with hEK from one donor yielded in a viability of well
above 85%, whereas in models generated from the second donor the vi-
ability was decreased to 50.4% only. A similar donor dependency is
observed for di-n-propyl disulphide that was classified as an irritant
in only 6 out of 30 test persons in the 4 hour patch test study
(Jírová et al., 2010). These ambiguous results are also reflected by the
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validation study and the outcomes of the EURL-ECVAM validation
study, where the substance was false-negative in 4 of 6 test runs
employing the EpiDerm™ and EpiSkin™ model (Kojima et al., 2013;
Spielmann et al., 2007).
A pronounced donor dependency was also described for the expres-
sion of metabolic enzymes in native human skin and several skin
models. These results indicate that the individual genetic background
of a cell donor is reflected in skin models generated from cells of this
donor (Oesch et al., 2014; Wiegand et al., 2014). Currently it cannot
be decided if the genetic background of the cell donors is the only rea-
son underlying the variation of the irritant response observed here.
However, since di-n-propyl disulphide and 1-bromohexane show dis-
cordant results between different cell donors, future validation studies
may profit from replacement of the critical test substances in the
OECD test guideline by less ambiguous substances.
Of the 10 non-irritating substances, 1-bromo-4-chlorobutane (sub-
stance 1), cinnamaldehyde (substance 4) and 4-methylthio-benzalde-
hyde (substance 2) were falsely classified as irritants in all
laboratories. This resulted in a specificity of 70% (Fig. 4), which is within
the acceptance limit of the performance standards. Despite their in vivo
classification as non-irritants, these substances are known to yield false
positive results in epidermalmodel-based skin irritation tests (Alépée et
al., 2010; Jung et al., 2014; Kojima et al., 2013; Spielmann et al., 2007).
Taken together, with an accuracy of 80% the OS-REp skin irritation test
is sufficiently accurate to meet the acceptance criterion of ≥75%. The
predictive capacity demonstrated here is comparable or even exceeding
previous validation studies—which is a remarkable result as all partic-
ipating laboratories established independent cell lots andmanufactured
OS-REp model batches on their own.
After receiving a training, the OS-REp skin irritation test could be
used by laboratories for regulatory accepted skin irritation testing inde-
pendent of commercially available epidermis models. To increase the
within-laboratory-reproducibility, special care has to be taken to train
the responsible staff in the procedures. In addition, for guaranteed re-
producibility and predictive capacity of the results, strict quality criteria
have to be achieved. Besides compliance with the quality criteria listed
in the performance standards, we suggest that a naïve laboratory that
intends to use the OS-REp protocol for regulatory purposes has to dem-
onstrate sufficient capability in a proficiency exercise employing the 20
reference test substances listed in the performance standards (OECD,
2015b).
In conclusion, the present catch-up validation study demonstrates
the capacity of the OS-REp-based skin irritation test to discriminate be-
tween skin irritating and non-irritating substances with a high overall
accuracy of 80%.With the exception of the within-laboratory-reproduc-
ibility, all performance standards of the OECD test guidelineweremet or
even exceeded, even though the study was the first to comprise the in-
dependentmanufacturing of tissuemodels in all three participating lab-
oratories. Therefore, after further optimization the test method is
moving in the direction of being a full standalone replacement of the
Draize in vivo skin irritation test, and the OS-REp skin irritation test
might set a precedent for further open source models in the framework
of alternative testing.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.tiv.2016.07.008.
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